Animol Discovery, Inc. Announces Series B Financing of $34.0 million to Advance Its Pipeline of Novel Veterinary Pharmaceuticals
Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, today announced it has raised $34.0 million in Series B financing. The investment was led by Novalis Lifesciences, with participation from Finistere Ventures and existing investor Anterra Capital. The proceeds allow the company to expand and advance its pipeline of novel active pharmaceutical ingredients through clinical development and further enhance its cutting-edge drug discovery platform.
The $40Bn animal health industry continues to demand novel medicines to treat infectious and chronic diseases in companion and production animals. Recent successes, such as Apoquel™ from Zoetis and Nexguard™ from Boehringer Ingelheim, demonstrate the potential to build towards blockbuster franchises in the sector with novel pharmaceutical products.
“Pet parents and livestock farmers continue to demand novel veterinary pharmaceuticals that can protect animals against diseases and improve quality of life,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “Despite this strong demand, innovation is lagging. At Animol, we seek to address this innovation gap by leveraging the most advanced tools from human pharma to bring forward a wealth of new medicines that can benefit animals and the people who care for them.”
Founded in 2020 and incubated by Anterra Capital, Animol is pioneering the use of DNA Encoded Library (DEL) drug discovery technology coupled with powerful machine learning approaches to enable the rapid discovery of novel veterinary medicines.
“We have built Animol on the same cutting edge discovery techniques that we are using to disrupt drug discovery in human pharma (ZebiAI - acquired by Relay Therapeutics) and crop protection (Enko Chem),” said Philip Austin, Managing Partner at Anterra Capital. “Translating these tools to the massive opportunity available in veterinary pharma was the next obvious step and we are already seeing their use successfully build into a rich pipeline of promising compounds.”
Animol also announced that Marijn Dekkers PhD, founder & chairman of Novalis LifeSciences LLC will join the Board of Directors. Dr. Dekkers formerly served as the CEO of Bayer AG, and as the CEO of Thermo Fisher Scientific, Inc. At Bayer he oversaw one of the largest global animal health companies.
“Most current medicines in the $40B veterinary pharma market are derived from drugs that have been originally developed for humans. There is of course nothing wrong with that, but there are many animal-specific diseases that require a targeted effort. I like Animol Discovery’s approach to use its breakthrough drug discovery platform to specifically address significant unmet needs in animals. I am looking forward to working with the team to optimize the opportunity ahead,” said Dr. Dekkers.
“It is a great pleasure to be able to welcome Marijn Dekkers to our Board of Directors. Dr. Dekkers is an exceptional industry leader with a track record of turning innovation into successful businesses across the spectrum of life sciences, including in animal health,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “He is an excellent addition to our team of experienced industry leaders.”
“I am also delighted to bring Doug Hutchens on board as chief scientific officer. Dr. Hutchens brings a wealth of industry experience in animal health research and product development; having someone who has also served as Chief Veterinary Officer within a major animal health company brings huge value to our expanding team,” added Dr. Plant.
“I am thrilled by the prospect of joining Animol’s dynamic and experienced team as chief scientific officer,” said Doug Hutchens, DVM, PhD. “The company’s ability to interrogate protein targets with billions of DNA-tagged molecules and, using DNA sequencing, identify selective inhibitors from numerous diverse chemical families is game changing in animal health drug discovery. Leveraging these data with proprietary, highly predictive machine learning algorithms, is enabling the identification of novel drug-like compounds in a matter of weeks from the initial DEL screen. This technology platform greatly expands the opportunities, significantly increases the probability, and accelerates the timeline in developing new classes of therapeutic molecules.”
Animol is a pioneer in using state of the art drug discovery technology to discover small molecule active pharmaceutical ingredients to transform standards of care in veterinary medicine. The company is reducing the time and cost to discover novel active ingredients utilizing DNA-encoded libraries, machine learning/AI and structure-based design.
Animol is a private company based in Boston, Massachusetts. For more information see www.Animol-discovery.com
About Novalis LifeSciences LLC
Novalis LifeSciences LLC is an investment and advisory firm for the Life Science industry that was founded in 2017 by Marijn E. Dekkers. With a team of experienced operating executives from the Life Science industry, Novalis funds and advises visionary Life Science entrepreneurs. In addition to making financial investments, Novalis provides strategic and operational advice to portfolio companies that are at a critical growth stage in their development. For more information, visit www.novalislifesciences.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Dr. Andrew Plant
Animol Discovery, Inc.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Study From Egon Zehnder and Kearney Debunks the Myth of a Workplace Generational Divide28.9.2022 16:00:00 CEST | Press release
Egon Zehnder, the world’s preeminent leadership advisory firm, in partnership with Kearney, a leading global management consulting firm, today released findings from a new survey with over 8,000 respondents from eight different countries dismissing the myth of a generation divide in the workplace and showing that despite what is often believed, Gen Z, Millennials, Gen X and Boomers are more alike than different when it comes to workplace matters. The survey, titled “Different Generations, Same Ideals: What Workers of All Ages Value in their Jobs,” analyzed the similarities and differences among generations and found that they share more commonalities, especially when it comes to personal well-being, work-life balance, and desired traits from leadership. The most notable difference between the generations is how each group defines and plans to achieve their career desires. Key Findings from the survey include: Personal well-being, stability, and work-life balance matter more than money
BYD Announces Pre-sale Prices of European Passenger Car Range28.9.2022 15:35:00 CEST | Press release
BYD announces the pre-sale prices of its new European passenger car range. The world’s leading manufacturer of new energy vehicles and power batteries immediately introduces three full-electric passenger vehicles which will be delivered to Norway, Sweden, Denmark, the Netherlands, Belgium, Luxembourg and Germany. Before the end of the year customers in France and the United Kingdom will also have access to BYD’s zero-emission vehicles. After that, more dealers will be appointed supporting BYD’s plans to cover all major markets in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005587/en/ BYD Europe Product Premiere 2022 The pre-sale price for the BYD ATTO 3 is € 38,000. The BYD HAN and TANG pre-sale prices are € 72,000. These pre-sale prices apply to Germany as a reference for Europe and may differ from country to country. The three full-electric BYD vehicles are technologically advanced and well-suited to the e
Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany28.9.2022 15:27:00 CEST | Press release
Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany. The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy(*) such as Gallium-68 generator and n.c.a Lutetium-177. Developed by Monrol R&D teams, these products are widely used in the production of radiopharmaceuticals for cancer patients. The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services. Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations. The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros. (*) Targeted radioligand therapy is an innovative approach to cancer treatment that is considered to
Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations28.9.2022 15:00:00 CEST | Press release
Fore Biotherapeutics (Fore Bio), a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to FORE8934, its investigational, novel, small-molecule, orally available inhibitor for the treatment of patients with cancers harboring BRAF Class 1 (V600) and Class 2 (including fusions) alterations who have exhausted prior therapies. The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A drug that receives Fast Track designation may become eligible for Accelerated Approval, Priority Review, or Rolling Review if relevant criteria are met. “The FDA's Fast Track Designation for FORE8394 underscores the urgent need faced by patients with advanced BRAF-muted cancers who have no other options,” said Stacie
Quectel Announces New SC680A LTE Smart Module to Drive Digital Transformation and Machine Vision AI Applications28.9.2022 15:00:00 CEST | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces that it has released its new SC680A smart module which features broad connectivity options including LTE Cat 6, Wi-Fi 802.11ac and Bluetooth 5.0 with powerful system performance and rich multimedia functions. The SC680A smart module is targeted towards mid-tier IoT devices including POS and payment terminals, industrial handhelds for logistics and warehousing, in-vehicle infotainment and dashcam solutions as well as micro-mobility applications and small electric cars. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005031/en/ Quectel's new SC680A LTE smart module (Photo: Business Wire) “We are excited to introduce another highly integrated smart module which gives global customers more flexibility in their IoT device designs,” said Norbert Muhrer, President and CSO of Quectel. “It enables a variety of industrial and consumer IoT verticals with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom